Publication
Clinical Benefit of Pembrolizumab in Lynch Syndrome-Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report.
Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki, Aya Tokinaga-Uchiyama, Katsuyuki Konnai, Hiroto Narimatsu, Yukihiko Hiroshima, Haruya Saji
- Source
- PubMed
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260909-000004
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first-line maintenance therapy, and pembrolizumab achieved a durable response in recurrent…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available